The goal of this clinical trial is to evaluate the efficacy and safety of rituximab(RTX) and mycophenolate mofetile(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).
Children with a definite diagnosis of SDNS are included in the study during relapse treatment.
Age 3-16 years.
Steroid dependent dose≤0.3mg/kg/day.
Cumulative steroid use for ≥6 months.
Diagnosis of secondary NS, such as secondary to lupus nephritis, hepatitis B-related nephritis, purpura nephritis, etc.
Anti-neutrophil cytoplasmic antibodies(ANCA) positive or complement C3 level decreased.
Diagnosis of hereditary nephrotic syndrome.
Full dose of prednisone (2mg/kg/day, maximum 60mg) are used for 14 days after relapse and urine protein don't turn negative.